Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net loss | $(14,522) | $(25,848) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 3,929 | 29,764 |
| Stock-based compensation expense | 9,776 | 11,179 |
| Net (gains) losses on equity securities | (2,022) | 1,425 |
| Deferred income taxes | (10) | (770) |
| Accretion of discounts on marketable investment securities | (454) | (1,435) |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's D&A?
- Castle Biosciences (CSTL) reported D&A of $3.93M in Q1 2026.
- How has Castle Biosciences's D&A changed year-over-year?
- Castle Biosciences's D&A decreased by 86.8% year-over-year, from $29.76M to $3.93M.
- What is the long-term trend for Castle Biosciences's D&A?
- Over 4 years (2021 to 2025), Castle Biosciences's D&A has grown at a 86.0% compound annual growth rate (CAGR), from $3.41M to $40.77M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Castle Biosciences's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude